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Most EE found (often insignificant) cost reductions resulting 
from the interventions, but only two studies explicitly com-
bined changes in costs with data on effectiveness to cost-
effectiveness ratios (ratio of additional costs to additional ef-
fects).  Conclusions: Medically unexplained symptoms cause 
relevant annual excess costs in health care that are compa-
rable to mental health problems like depression or anxiety 
disorders and which may be reduced by interventions tar-
geting physicians as well as patients. More extensive re-
search on indirect costs and cost-effectiveness is needed. 
 Copyright © 2012 S. Karger AG, Basel 
 Background 
 Patients with medically unexplained symptoms suffer 
from patterns of persistent bodily complaints indicating 
no sufficiently explanatory physical pathology despite 
frequent intensive diagnostic efforts. Such patients pres-
ent a substantial portion of patients in all health care sec-
tors, particularly in primary care, where prevalence rates 
between 16 and 32% have been reported  [1–3] . Multi-
ple medical symptoms found in medically unexplained 
symptoms are associated with negative treatment out-
comes in other disorders, e.g. depression or anxiety dis-
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 Abstract 
 Objective: To review cost-of-illness studies (COI) and eco-
nomic evaluations (EE) conducted for medically unexplained 
symptoms and to analyze their methods and results.  Meth-
ods: We searched the databases PubMed, PsycINFO and
National Health Service Economic Evaluations Database of 
the University of York. Cost data were inflated to 2006 using 
country-specific gross domestic product inflators and con-
verted to 2006 USD purchasing power parities.  Results: We 
identified 5 COI and 8 EE, of which 6 were cost-minimization 
analyses and 2 were cost-effectiveness analyses. All studies 
used patient level data collected between 1980 and 2004 
and were predominantly conducted in the USA (n = 10). COI 
found annual excess health care costs of somatizing patients 
between 432 and 5,353 USD in 2006 values. Indirect costs 
were estimated by only one EE and added up to about 18,000 
USD per year. In EE, educational interventions for physicians 
as well as cognitive-behavioral therapy approaches for pa-
tients were evaluated. For both types of interventions, effec-
tiveness was either shown within EE or by previous studies. 
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orders  [4] , and are connected to high health care utiliza-
tion  [5, 6] , causing substantial costs. Health care utiliza-
tion and costs are two different measures of resource 
usage. While health care utilization is easier to interpret 
for clinicians, costs are easier to interpret for economists. 
Presenting resource usage as costs rather than utilization 
allows summing cost from different cost areas to total 
costs, enabling more compressive analysis than for utili-
zation data. For this reason, resource use should be pre-
sented as cost data. The costs of medically unexplained 
symptoms have two origins: resources utilized for health 
care (direct costs) and productivity losses arising primar-
ily from morbidity-related sickness absence (indirect 
costs). The question about relevance of single cost catego-
ries strongly depends on the perspective taken by the 
study. From a societal perspective, all costs (including in-
direct costs) are relevant, whereas from a payer’s perspec-
tive only direct medical costs may be relevant. Direct and 
indirect costs together constitute the economic burden of 
medically unexplained symptoms, which can be quanti-
fied via cost-of-illness studies (COI). In COI, the costs of 
an illness are estimated by measurement and monetary 
valuation of health care utilization and lost productivity 
in patient samples or by extraction of this information 
from routine data. As health care systems are confronted 
with limited resources and a large proportion of medical 
health care utilization of patients with medically unex-
plained symptoms can be regarded as ‘misspent’, several 
economic evaluations (EE) investigated how the costs of 
medically unexplained symptoms can be reduced by spe-
cific interventions  [7, 8] . There are different types of EE: 
cost-minimization analyses (CMA) address the question 
whether an intervention results in lower health care costs. 
However, treatment decisions should not be based on cost 
considerations alone. Instead, cost data should always be 
combined with data on effectiveness in order to create 
cost-effectiveness analyses (CEA), which use clinical pa-
rameters like gained life years or recovered cases as a 
measure of effectiveness  [9] . Health economists even pre-
fer so-called cost-utility analyses with quality-adjusted 
life years (QALYs) as the measure of effectiveness. In or-
der to calculate QALYs, life years are weighted with a 
preference-based index of their health-related quality of 
life, normally estimated from questionnaire-based as-
sessments of a patient’s health-related quality of life. Typ-
ically, cost-effectiveness refers to the ratio of the differ-
ences in costs and differences in health effects when two 
or more treatment strategies are compared (e.g. interven-
tion vs. control). This ratio is called ‘incremental cost-
effectiveness ratio’ and can be interpreted as the cost of 
one effect unit resulting from performing the interven-
tion rather than the control  [10] . Whereas COI present 
information only on the economic burden of a disease, 
EE can assist decision makers in the allocation of scarce 
resources by providing information about the input-out-
put ratio of a health care technology.
 Though theoretical standards and guidelines for COI 
or EE exist, general methods, data sources and analytical 
techniques in the literature are heterogeneous. One rea-
son may be that health economic studies are often con-
ducted ‘piggy back’ to clinical studies or as secondary 
analyses, enforcing compromises in study design. Sys-
tematic reviews of the literature may help to structure 
methods used in COI and EE and to facilitate the inter-
pretation of their results.
 While reviews about economic aspects of specific sin-
gle disorders like fibromyalgia  [11] or irritable bowel syn-
drome  [12] already exist, to our knowledge, this is the first 
systematic review of health economic literature in the 
field of medically unexplained symptoms in general. The 
aim of our study is to provide the first systematic review 
of COI and EE in medically unexplained symptoms.
 Methods 
 Data Sources and Search Strategy 
 We conducted a chronological unlimited literature search 
(until January 2010) in the databases PubMed, PsycINFO and the 
National Health Service Economic Evaluations Database of the 
University of York as well as in the reference lists of identified 
studies. According to the current development process of the S3-
guideline (guideline with all components of a systematic develop-
ment: logical structure of clinical algorithms, consensus, evi-
dence base, decision analyses and outcome analyses) for nonspe-
cific, functional and somatoform bodily complaints (http://www.
awmf.org/leitlinien/detail/anmeldung/1/ll/051-001.html) of the 
Association of the Scientific Medical Societies in Germany 
(AWMF), we used the following search terms: (‘somatoform dis-
order’ OR somatiz * OR somatis * OR ‘conversion disorder’ OR 
multisomatoform * OR ‘medically unexplained symptoms’ OR 
‘medically unexplained illness’ OR psychogen * OR nonorgan * OR 
(psychosom * syndrome) OR ‘functional somatic syndrome’ OR 
‘functional syndrome’ OR hypochondri * OR ‘illness phobia’ OR 
‘health anxiety’ OR ‘body dysmorphic disorder’ OR dysmorpho-
phobia) and (cost OR economic OR expenditure). Search terms 
were adjusted to meet the formal specifications of the databases.
 Selection Criteria 
 Studies were included if they reported original cost or cost-
effectiveness data for medically unexplained symptoms. We ex-
cluded reviews, studies reporting results of other studies, studies 
not meeting diagnostic criteria, studies that used economically 
relevant parameters (e.g. being a ‘high utilizer’) as inclusion cri-
teria and studies which were not in the English language.
 Economics of Medically Unexplained 
Symptoms 
Psychother Psychosom 2012;81:265–275 267
 Methodological Assessment, Extraction and Analysis of Cost 
Data 
 We analyzed general methodological issues (e.g. study type, 
recruitment setting, diagnostic criteria, sample size, sources of 
cost data) and minimal quality (e.g. calculation and presentation 
of cost data and effectiveness) as well as cost results. If necessary, 
cost data were transformed to annual values, inflated to the year 
2006 using country-specific price indices of gross domestic prod-
ucts and converted to USD using purchasing power parities to 
account for differences in purchasing power between countries 
 [13] . Given sufficient data, we estimated excess costs (see Appen-
dix) for COI and cost differences (e.g. before and after interven-
tion) for CMA and CEA.
 Results 
 Search results are shown in  figure 1 . We identified
42 studies that were analyzed in full text, of which 13 
studies were included: 5 COI, 6 CMA, and 2 CEA. We 
excluded 29 studies for several reasons, mainly because 
they did not meet diagnostic criteria, reported no costs
or used economic parameters as inclusion criteria
(for details, see online supplementary table  1, www.
karger.com/doi/10.1159/000337349). 
 Study Characteristics 
 General study characteristics are presented in  table 1 . 
The earliest studies came from the year 1986, the most 
recent one from 2008. The majority of studies (n = 10) 
were conducted in the USA  [7, 8, 14–20] , 2 in Great Britain 
and 1 in Germany. Patients were predominantly recruit-
ed in primary care settings (n = 7). The most often in-
cluded syndromes were ‘somatization’ (n = 6) and ‘soma-
tization disorder’ (n = 5). Diagnostic criteria differed 
largely between studies: half of the studies (n = 6) used 
DSM criteria (DSM-III or DSM-IV), the remaining stud-
ies used either the presence of medically unexplained 
symptoms assessed by chart reviews (n = 3) or patient 
self-report questionnaires and symptom checklists (n = 
3), or both of them (n = 1). The study design strongly de-
pended on the type of economic analysis (or vice versa): 
while COI were conducted alongside cohort studies with-
out intervention, EE of interventions were either pre-post 
cohort studies or randomized controlled trials (RCTs). 
Sample sizes ranged from 38 to 299, and all studies used 
patient level data for cost calculations. Except for Seive-
wright et al.  [21] , who used a health service perspective, 
no study explicitly stated the perspective from which the 
study was conducted. Cost estimates were predominant-
ly based on billing information or medical records ob-
tained from health care providers or payers, often com-
plemented by further investigations to assess costs not 
covered by payers ( table 1 ).
 Online supplementary  table 2 displays the cost catego-
ries considered. All studies assessed costs of outpatient 
physicians, and all but one assessed costs of inpatient 
care. Costs of emergency rooms and outpatient proce-
dures were assessed by 10 and 9 studies, respectively. Ten 
studies assessed an outpatient diagnostic procedure, 
most often for laboratory. Surprisingly, only 5 studies as-
sessed costs for drug use. Indirect costs were hardly re-
corded. Only Hiller et al.  [22] assessed productivity loss-
es due to sickness absence.
42 studies analyzed in full text
13 studies included
29 studies excluded
PubMed:
868 results
PsycINFO:
220 results
5 cost-of-illness
studies
2 cost-effectiveness
analyses
6 cost-minimization
analyses
8 economic
evaluations
NHS EED:
37 results
 Fig. 1. Flow chart of search results, study 
inclusion and study exclusion. 
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 Cost-of-Illness Studies 
 Table 2 shows total and excess costs found in COI. In 
values of 2006, 5 COI found mean annual health care 
costs ranging from 1,584 to 6,424 USD. Four of these stud-
ies calculated excess costs using either data from the gen-
eral population, average ‘Health Alliance Plan’ patients, 
patients below the somatization cutoff used, or a random 
patient group without somatization as comparator. Excess 
costs ranged from 432 to 5,353 USD. Reporting of percent-
ages of cost categories in overall costs was limited. Two 
studies found inpatient costs to account for a substantial 
part of total direct costs: Smith et al.  [14] found inpatient 
costs of 74% and Barsky et al.  [18] of 51%; the latter addi-
tionally reported inpatient costs to account for 68% of ex-
cess costs. Two further studies reported that diagnostic 
procedures accounted for about 40% of total direct costs 
 [16, 17] . McFall et al.  [19] showed that direct costs were 
primarily caused by medical treatment (57%) and drugs 
(11%), while only 32% stemmed from mental treatment.
 Economic Evaluations 
 General study characteristics of EE are shown in  ta-
ble 1 , details on intervention, health outcomes and costs 
in  table 3 . Studies can be grouped by whether the evalu-
ated interventions are targeting primary care physicians 
(PCP)  [7, 8, 15, 23] or the patients  [20–22, 24] . Interven-
tions targeting PCPs intended to strengthen PCPs’ abili-
ties to identify and manage patients with medically un-
explained symptoms. Interventions targeting patients 
were all based on cognitive behavioral therapy (CBT). Six 
studies were based on RCTs and three studies on pre-post 
cohorts. From the economic perspective, the majority of 
EE (n = 6) were CMA, questioning whether or not the in-
tervention was cost saving. Two studies were CEA  [21, 
23] , which put changes in costs in relation to changes in 
a measure of effectiveness.
 Interventions Targeting on PCPs 
 Consultation Letter. In three studies of a study group 
surrounding G.R. Smith  [7, 8, 15] , a consultation letter for 
PCPs was evaluated in terms of cost minimization. The 
letter informed physicians about clinical characteristics, 
course and prognosis of medically unexplained symp-
toms and gave recommendations on clinical patient man-
agement. It encouraged physicians to serve as the patient’s 
PCP and suggested regular appointments including phys-
ical examination and avoidance of hospitalizations, sur-
geries, diagnostic procedures and laboratory assessments, 
unless clearly indicated. In the oldest study  [7] , the cross-
sectional cost data of Smith  [5] were longitudinally fol-Ta
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lowed using a cost minimization approach. In the two 
younger studies, Smith and colleagues  [8, 15] recruited 
patients with medically unexplained symptoms and ana-
lyzed different subsamples of patients with somatization 
and somatization disorder. All three studies found sig-
nificant reductions of median medical or total costs in 
patients after the intervention. In the younger studies  [8, 
15] , cost changes for psychiatric services were analyzed 
and not found to change significantly. Health outcome 
was uniquely assessed using the ‘RAND health status 
measure’ ( table 3 ). Whereas Smith et al.  [7] found no sig-
nificant changes in health outcome, Kashner et al.  [8] and 
Smith et al.  [15] found significant improvements on the 
‘physical health’ axis of the RAND health status measure.
 PCP Training Program. One study evaluated a training 
package for PCPs ‘how to encourage patients with soma-
tized mental disorder to reattribute and relate physical 
symptoms to psychosocial problems’ in the sense of in-
cremental cost-effectiveness  [23] . Effectiveness was mea-
sured as number of patients that were no longer psychi-
atric cases according to the general health questionnaire. 
The authors found an insignificant overall cost reduction 
and an improved effectiveness, which slightly missed sig-
nificance (p = 0.058).
 Interventions Targeting Patients 
 We identified 4 studies evaluating different CBT ap-
proaches: CBT alone  [22] , CBT combined with a consul-
tation letter for PCPs  [24] , CBT combined with drug 
management by nurse practitioners  [20] and CBT com-
bined with a patient manual on the principles of CBT  [21] . 
Treatment outcomes were assessed by pertinent ques-
tionnaires, which mostly showed superiority for the in-
tervention group ( table 3 ). Three studies  [20, 22, 24] were 
conducted in terms of cost minimization and found re-
ductions in treatment costs which were only significant 
for median costs in one study  [24] . One study assessed 
indirect costs and found a significant reduction due to the 
intervention  [22] . Three studies reported the costs of the 
intervention  [20–22] , which mostly offset the reductions 
found in treatment costs. Only one study performed a 
CEA  [21] using the Health Anxiety Inventory as measure 
of effectiveness. From a health service perspective and 
adjusted for baseline variables, the authors found an in-
cremental cost-effectiveness ratio of 54 USD per Health 
Anxiety Inventory unit reduced, which can be interpret-
ed as follows: with every unit of Health Anxiety Inven-
tory reduction resulting from conducting the interven-
tion instead of the control, additional overall costs of
54 USD occur (compared to the control).
 Discussion 
 To our knowledge, this is the first systematic review
of health economic studies for medically unexplained 
symptoms. We found two main results: first, medically 
unexplained symptoms cause relevant excess costs per 
patient; second, interventions targeting PCPs’ diagnostic 
and patient management skills as well as CBT for patients 
have the potential to improve patients’ health status and 
to reduce costs.
 Strengths 
 This review has several strengths. We used a broad 
search strategy and included a wide spectrum of health 
economic study types leading to a comprehensive over-
view of existing health economic publications in the field 
of medically unexplained symptoms. The methodologi-
cal quality of the studies was described, analyzed and dis-
cussed in depth, indicating weaknesses that can be ad-
dressed in future research.
 Limitations 
 Our review has some limitations. Due to the hetero-
geneity and limited methodological quality of studies, it 
was hardly possible to apply strict quality criteria for the 
inclusion or exclusion of studies, though we presented 
all available evidence and tried to discuss important 
quality issues. Due to restrictions of access to respective 
literature or languages and to avoid arbitrariness in 
study inclusion, we did not consider dissertations, un-
published material or studies not in the English lan-
guage, which makes our review susceptible to publica-
tion bias. Four of 13 included studies originated from 
the same work group, using 2 samples of patients for two 
studies each, limiting the independence of the data. 
However, every study had a unique objective, and 3 of 
the 4 studies had unique patient samples. Comparabil-
ity of studies was limited due to differences in design, 
methods and year of study conduction. We used an un-
limited search period; but therapeutic possibilities, 
standards and health care systems change over time, 
which affects cost estimates. Differences in included 
cost categories further limited comparability. This was 
especially true for COI, for which cost comparisons be-
tween studies are more relevant than for CMA and CEA, 
which focus on comparisons of therapeutic alternatives. 
When comparing different estimates of excess costs, 
one must also note that these do not only depend on the 
costs of the disease but also on the comparator used to 
calculate the excess.
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 Methodological Quality of Included Studies 
 The quality of cost measurement and calculation
was – as far as assessable – adequate. A majority of cost 
calculations was based on administrative data from hos-
pital databases or billing information obtained from pay-
ers in COI as well as EE. This method tends to underes-
timate privately paid health care goods, which may be 
problematic when a societal perspective is used. Further, 
being a result of individual cost structures and local pric-
es, billing information from specific health care provid-
ers may be very inaccurate in reflecting the true econom-
ic impact of a disease. But the alternatives of using ques-
tionnaires or interviews to assess health care utilization 
also have disadvantages like underreporting or misre-
porting due to memory bias. A general problem was the 
definition of cost categories and the quantity of included 
cost categories, for which we found large differences be-
tween studies, resulting from different scopes and avail-
able data sources. This strongly hampered comparison of 
costs between studies. Labott et al.  [16] and Hiller et al. 
 [22] conducted the most comprehensive assessments of 
cost categories, but no study assessed nonmedical costs 
(e.g. for transport to physicians), and only Hiller et al.  [22] 
assessed indirect costs.
 The quality of presenting the health economic results 
was sometimes poor. Only one study stated the perspec-
tive from which the study was conducted  [21] . Yet the per-
spective of a study (e.g. society or payer) is crucial, be-
cause it determines the primary interest group of the 
study and which costs should or should not be included 
in the study. From a payer’s perspective, for example, in-
direct costs or private payments are usually irrelevant, 
but from a societal perspective, these costs are very im-
portant. Eight studies  [14, 16–20, 22, 24] did not report 
the year of costing. Due to inflation and changes in pric-
es and health care systems, it is essential for a reader to 
know the year cost data are referring to. Without this in-
formation, inflation adjustment and interpretation of 
costs are seriously hampered. Four EE reported cost data 
as median values, due to skewed cost data  [7, 8, 15, 24] . 
From the statistical point of view, medians may be more 
appropriate than means, but cost data should always also 
be reported as means for several reasons. Medians cannot 
be summed or subtracted (hampering the calculation of 
cost reductions or excess costs, for example) and pub-
lished cost data are often used as input in mean-based 
further research (e.g. cost-effectiveness models or budget 
impact analysis). Methods like bootstrapping  [25] can be 
used to account for skewed data when comparing mean 
cost data. Related to this issue, there is another problem 
concerning sample sizes. Due to the large variance and 
skewed nature of cost data, cost comparisons usually 
need larger sample sizes than comparisons of clinical ef-
fectiveness to detect differences at the significance level. 
Indeed, sample size was quite low (considerably below 
100) in 6 of 9 EE  [7, 8, 15, 21, 22, 24] . This presents a gen-
eral problem in health economics, because EE are often 
conducted as ‘piggy back’ studies in clinical trials which 
often need lower sample sizes due to lower variances of 
clinical parameters compared to cost data. Finally, RCT-
based EE of interventions for physicians were in fact clus-
ter RCTs, but no study indicated that cluster design was 
taken into account in statistical analyses.
 Cost-of-Illness Studies 
 COI showed that medically unexplained symptoms 
are associated with relevant annual excess costs in health 
care, ranging from 432 to 5,353 USD per patient in prices 
of 2006. Recent reviews found comparable annual excess 
costs per patient of up to 5,871 USD for depression  [26] , 
and of up to 3,042 USD for anxiety disorders  [27] . Inter-
estingly, excess costs showed much more variability (by 
factor 12) than total costs (by factor 4), indicating a larg-
er uncertainty in estimating excess costs compared to to-
tal costs. This may (in part) result from the diagnostic 
heterogeneity of the control groups, which showed cost 
variations by factor 27. The question how to estimate a 
disorder-specific cost-excess is of general importance in 
COI, but no general recommendations exist on handling 
this issue.
 The heterogeneity of reported cost categories hampers 
detailed interpretations or comparisons of single cost cat-
egories. Nevertheless, we found two tendencies in the 
studies. Two studies each found high portions of direct 
costs for inpatient treatments (68–74% of excess costs  [14, 
18] ) and – using a differing cost stratification – diagnos-
tic procedures (approx. 40%  [16, 17] ). These findings in-
dicate the potential for cost savings by sufficient treat-
ment of medically unexplained symptoms avoiding un-
necessary diagnostics and hospital stays.
 Whereas all studies measured direct costs, we found a 
lack of analyzing indirect costs. Only Hiller et al.  [22] es-
timated indirect costs in an EE. Though restricted to 
sickness absence from work, the preintervention indirect 
costs were 3 times the direct costs and were much more 
reduced by the intervention than direct costs (–35% vs. 
–19%). It can be suspected that overall indirect costs in-
cluding costs resulting from reduced productivity at work 
may even be much higher. This underscores the impor-
tance of measuring and analyzing indirect costs connect-
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ed to medically unexplained symptoms from a societal 
perspective.
 Economic Evaluations 
 We identified 9 EE in two waves of studies investigat-
ing the management of medically unexplained symp-
toms. In a first wave of studies, interventions targeted 
PCPs, evaluating consultation letters  [7, 8, 15] and educa-
tional training  [8, 15, 23] . In a second wave of studies, the 
focus moved to CBT approaches for patients  [20–22, 24] . 
Almost all studies found cost reductions during follow-
up compared to before treatment – yet not always pre-
sented as mean differences and often insignificant.
 Based on the studies we found, a comparison of inter-
ventions for PCPs and CBT is hardly possible. Though 
intervention costs were hardly stated for PCP trainings, 
they should be considerably lower than for CBT, because 
PCP training costs are divided among a couple of pa-
tients, whereas CBT costs occur with every patient. If 
stated, intervention costs for CBT often offset cost reduc-
tions resulting from CBT. However, the longest follow-up 
was 24 months, and one might speculate that CBT may 
show further cost savings after this time point. Allen et 
al.  [24] found a combination of CBT and a consultation 
letter to be more effective on a couple of effectiveness 
measures – a finding that is also provided by the litera-
ture  [28] – and less costly (on the median level) than con-
sultation letter alone.
 In addition to changes in costs, EE of interventions 
should always relate to changes in effectiveness. In this 
respect, we found a general lack in methodology in 6 out 
of 8 EE, which were CMA  [7, 8, 15, 20, 22, 24] . CMA are 
subject to serious criticism, since they ignore differences 
in the health gain or loss of an intervention  [9] . Ignoring 
health effects is very problematic, because a cost saving 
intervention might result in adverse health effects. On the 
other hand, a more costly intervention might result in 
health gains that are worth the additional costs – depend-
ing on a society’s economic properties, health preferences 
and willingness to pay for health care goods. Though not 
related to cost data, health outcomes of the interventions 
were either assessed or cited in all CMA. These health 
outcomes indicate that health status was either improved 
or unchanged by the interventions. Combined with the 
reductions found in costs, this can be interpreted in favor 
of the interventions.
 Implications for Clinical Practice 
 The results of our analysis indicate that two aspects are 
crucial for patient outcome and to delimit health care 
costs: first, the sensitization of caregivers for medically 
unexplained symptoms, and second, provision of effec-
tive care models. This affects physicians’ knowledge and 
skills in diagnosis and management of patients with med-
ically unexplained symptoms  [29] . Physicians should be 
skilled in the basic communication techniques to handle 
functional patients. PCPs are the center of attention, as 
they are usually the first caregivers who functional pa-
tients contact. Instead of unnecessary diagnostic proce-
dures, a ‘watchful waiting’ strategy should be applied 
 [30] . Physicians’ excuses from work should be given very 
critically; instead, graded activation and exercise should 
be advised  [31] . Instead of poorly prepared referrals to 
specialists or to hospital, multidisciplinary, stepped and 
collaborative care models should be established  [28, 32] . 
Premature pension should be avoided and psychotherapy 
like CBT should be applied when appropriate.
 Implications for Future Research 
 The health economic quality of COI and CEA in the 
field of medically unexplained symptoms should be fur-
ther improved. This should comprise the use of large 
enough sample sizes, reporting of sufficient health eco-
nomic information including mean cost data, perspec-
tive, pricing year, and, finally, the calculation of cost-ef-
fectiveness or cost-utility rather than cost minimization. 
Given a societal perspective, indirect costs should be as-
sessed in particular because the strong subjective health 
impairment of patients with medically unexplained 
symptoms may substantially impair their productivity. 
More extensive research on cost-effectiveness is needed. 
Overall, the study of Seivewright et al.  [21] presents the 
best example of a state-of-the-art EE available in the field 
of medically unexplained symptoms. For further infor-
mation, well-accepted literature is available for planning, 
conducting, analyzing and presenting EE  [33] .
 Conclusions 
 Medically unexplained symptoms are associated with 
relevant annual excess costs in health care. Large propor-
tions of these costs seem to be caused by hospital stays, 
diagnostic procedures and medical treatments. Regard-
ing interventions, we found evidence supporting superi-
ority of training for PCP to recognize and manage pa-
tients with medically unexplained symptoms compared 
to no training from the health economic perspective. Re-
garding CBT, the health economic evidence remains 
more uncertain due to the intervention costs – though 
 Konnopka  /Schaefert  /Heinrich  /
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favorable cost-effectiveness compared to ‘usual care’ is 
indicated. We found a lack of research on indirect costs, 
which seem to be high in medically unexplained symp-
toms and should be a focus for further research. EE 
showed a strong methodological focus on cost reductions 
with a clear neglect of cost-effectiveness. More effort on 
(long-term) cost-effectiveness should also be a focus of 
future research.
 Appendix: Glossary of Economic Terms 
 Cost-effectiveness analysis (CEA): A subtype of  economic 
evaluations using clinical measures for medical effectiveness (e.g. 
life years gained, anxiety-free days, PHQ-15 score, CGI score).
 Cost-minimization analysis (CMA): A subtype of  economic 
evaluations using no measure of medical effectiveness. As this 
type compares only costs, it should only be used if medical effec-
tiveness is expected to be identical in the compared alternatives. 
Because this is mostly not the case, use of CMA is strongly lim-
ited.
 Cost-of-illness study (COI): In a COI, one estimates the  direct 
costs and/or  indirect costs associated with a disease or disease 
group (e.g. costs of depression, costs of anxiety disorders) or a risk 
factor (e.g. costs of smoking).
 Cost-utility analysis: A subtype of  economic evaluations using 
 quality-adjusted life years as measure for medical effectiveness.
 Direct costs: Monetarily valued resource use resulting from 
the treatment of a disease. Occur as medical costs (e.g. for hospital 
use, physician use, pharmaceuticals) and nonmedical costs (e.g. 
administration costs, travel costs, research costs). Normally di-
rect costs are calculated by multiplying utilization data with costs 
per unit used.
 Economic evaluation (EE): In an EE, one compares an inter-
vention (e.g. a new drug, a new therapy, a prevention program) 
with an alternative (e.g. gold standard, treatment as usual, no 
treatment) regarding their costs and their medical effectiveness. 
Depending on the measure of medical effectiveness  cost-minimi-
zation analysis, cost-effectiveness analysis  and cost-utility analyses 
are distinguished as subtypes of EE. The primary outcome of an 
EE is the so called  incremental cost-effectiveness ratio .
 Excess costs: Costs that can be attributed to a specific disease 
of interest in addition (excess) to costs that result from other dis-
eases. Can be estimated e.g. by comparing the cost of patients with 
the disease of interest with ‘representative’ or matched patients 
without the disease of interest.
 Incremental cost-effectiveness ratio (ICER): This is the ratio 
of the additional costs (C) to the additional medical effects (E)
of an intervention (I) compared to an alternative (A) within
an  economic evaluation . The ICER is calculated as ICER =
(C I – C A )/(E I – E A ) and constitutes the costs for an additional 
medical effect gained by using the intervention instead of the 
alternative.
 Indirect costs: The monetarily valued loss of productivity as-
sociated with a disease. Occur primarily as reduced productivity 
at work, sickness absence, early retirement or premature mortal-
ity. Normally indirect costs are calculated by multiplying loss of 
productivity time with wages.
 Perspective: The (economic) perspective determines the cost 
categories that should be assessed in a  cost-of-illness study or an 
 economic evaluation . If a study is conducted from a payer’s per-
spective only costs relevant for the payer (normally only  direct 
costs ) are assessed. From a societal perspective (which is recom-
mended in the literature) all relevant costs (including also  indirect 
costs ) should be assessed. Further possible perspectives are a pa-
tient perspective or a provider perspective.
 Quality-adjusted life years (QALY): In quality-adjusted life 
years, time (e.g. lived time or life years gained) is weighted with 
an index value of a person’s health-related quality of life. This in-
dex normally ranges from 0 (death) to 1 (full quality of life) and 
is either calculated from specific quality of life questionnaires 
(e.g. EQ-5D or SF-6, SF-12) or directly measured via methods like 
time trade-off or standard gamble. For example, 1 QALY can be 
1 year lived with a quality of life index of 1.0, or 2 years lived with 
a quality of life index of 0.5 (= 2  ! 0.5 QALYs). QALYs are the 
measure of medical effectiveness in  cost-utility analysis and are 
recommended as standard measure of medical effectiveness for 
 economic evaluations .
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